How to Get Tresiba in New Hampshire

What Is Tresiba and Why Might a New Hampshire Provider Prescribe It

Insulin degludec (brand name Tresiba) is an ultra-long-acting basal insulin with a half-life exceeding 25 hours and a duration of action beyond 42 hours. A New Hampshire provider might choose it over insulin glargine or insulin detemir because it produces a flatter, more predictable pharmacokinetic profile that reduces nocturnal hypoglycemia risk in both type 1 and type 2 diabetes.

The FDA approved insulin degludec in September 2015 for adults with type 1 and type 2 diabetes and later expanded the label to children aged one year and older. The full prescribing information is publicly available through the FDA's drug database. [1]

The key DEVOTE trial (N=7,637, NEJM 2017) compared insulin degludec 100 U/mL to insulin glargine 100 U/mL in patients with type 2 diabetes at high cardiovascular risk. Degludec was non-inferior for major adverse cardiovascular events (hazard ratio 0.91 to 95% CI 0.78 to 1.06) and produced a 40% relative reduction in severe hypoglycemia versus glargine (rate ratio 0.60 to 95% CI 0.48 to 0.76, P<0.001). [2] That hypoglycemia advantage is often the deciding factor when a New Hampshire clinician switches a patient from a standard basal insulin.

The American Diabetes Association's Standards of Care recommend ultra-long-acting basal insulins like degludec for patients who experience recurrent hypoglycemia on longer-acting agents, citing the class's lower within-patient variability. [3] The Endocrine Society similarly notes that insulin degludec's flexible dosing window, which allows dose-time shifts of up to eight to nine hours without loss of glycemic control, may benefit patients with irregular schedules. [4]

Who Can Prescribe Tresiba in New Hampshire

Any licensed prescriber in New Hampshire with full prescriptive authority can write a Tresiba prescription. That includes MDs, DOs, nurse practitioners (NPs), physician assistants (PAs), and clinical pharmacist practitioners who hold a collaborative practice agreement.

New Hampshire grants NPs full practice authority. Under RSA 326-B:11, NPs may independently diagnose, treat, and prescribe Schedule II through V controlled substances as well as non-controlled drugs like insulin without a collaborating physician. [5] PAs in NH prescribe under a supervising physician agreement but retain broad formulary access, including basal insulins.

Endocrinologists, internal medicine physicians, and family medicine physicians all routinely prescribe insulin degludec in outpatient and telehealth settings. Patients do not need a specialist referral to obtain Tresiba in New Hampshire; a primary care visit is sufficient for most straightforward type 2 diabetes cases.

How to Get a Tresiba Prescription Through Telehealth in New Hampshire

Telehealth is fully legal in New Hampshire for new and established patients requiring prescription medications. NH RSA 329:1-d governs telehealth prescribing and permits synchronous audio-video visits as the basis for new prescriptions. [6]

The typical telehealth pathway has four steps. First, the patient completes an intake form covering diabetes history, current medications, most recent A1C, and any documented hypoglycemia events. Second, a licensed NH provider conducts a synchronous video visit, usually 20 to 30 minutes. Third, if clinically appropriate, the provider sends an electronic prescription to the patient's preferred pharmacy. Fourth, the patient picks up or receives the medication.

Most telehealth platforms serving New Hampshire can complete steps one through three within 24 to 48 hours of scheduling. With mail-order pharmacy fulfillment, the patient typically receives Tresiba within two to five business days of the visit. Local NH pharmacies can fill the same day or next day in most cases.

A practical decision framework for NH telehealth Tresiba access:

1. Confirm your telehealth provider holds an active NH medical license (check the NH Office of Professional Licensure and Certification at oplc.nh.gov).
2. Upload your most recent labs before the visit to avoid delays (see the labs section below).
3. Ask the provider specifically whether they will submit prior authorization on your behalf if your plan requires it, because some telehealth platforms do not offer PA support.
4. Verify your pharmacy has Tresiba 100 U/mL FlexTouch or 200 U/mL FlexTouch in stock before the prescription is sent, since the 200 U/mL pen is sometimes backordered at smaller independent pharmacies.

Research published in JAMA Internal Medicine found that patients using telehealth for diabetes management achieved A1C reductions comparable to those seen in in-person cohorts, with a mean A1C drop of 1.3 percentage points over 12 months in a rural population. [7] That evidence base supports telehealth as a clinically sound, not merely convenient, pathway for insulin initiation.

What Labs Are Needed Before Starting Tresiba in New Hampshire

A prescriber in New Hampshire will typically want the following before initiating insulin degludec. None of these are regulatory requirements, but they reflect standard of care.

Hemoglobin A1C. Most providers want an A1C drawn within the past three months. An A1C above 7.0% in type 2 diabetes or above 7.5% in type 1 diabetes typically supports the clinical indication for basal insulin intensification. The ADA defines an individualized A1C target, generally 7.0% for most non-pregnant adults, with higher targets acceptable for patients at risk of hypoglycemia. [3]

Fasting glucose or a recent continuous glucose monitoring (CGM) download. CGM data from a device like Dexcom G7 or Libre 3 provides far more actionable information than a single fasting glucose, and many NH telehealth providers now accept a 14-day CGM report in lieu of a fasting lab.

Basic metabolic panel (BMP). Kidney function (eGFR and serum creatinine) matters because renal impairment alters hypoglycemia risk. The FDA label notes no dose adjustment is formally required in renal impairment, but monitoring is intensified. [1]

Thyroid-stimulating hormone (TSH). Uncontrolled hypothyroidism raises insulin requirements. TSH is not always mandatory, but most endocrinologists and internists request it at least once per year for diabetic patients.

Body weight and BMI. Insulin dosing is weight-based. Starting doses for type 2 diabetes are typically 10 units once daily or 0.1 to 0.2 units per kilogram, per the prescribing information. [1]

Studies in PubMed-indexed journals confirm that pre-visit lab availability reduces telehealth visit time and increases prescribing confidence, with one systematic review noting that structured diabetes care protocols cut time-to-prescription by approximately 30% versus unstructured visits. [8]

Insurance, Prior Authorization, and Cost in New Hampshire

Most commercial insurance plans sold on the New Hampshire health exchange, as well as employer-sponsored plans, cover insulin degludec but place it on a non-preferred tier requiring prior authorization (PA). NH Medicaid (NH Healthy Families and AmeriHealth Caritas New Hampshire) does not currently list Tresiba on its preferred drug list, which means Medicaid beneficiaries face either a PA process with a low approval rate or an out-of-pocket expense. [9]

Prior authorization documentation. A standard NH commercial PA for Tresiba typically requires: a confirmed diagnosis of type 1 or type 2 diabetes with ICD-10 code, most recent A1C result, evidence of a trial of at least one preferred formulary basal insulin (usually glargine biosimilar), and clinical justification for step-up (most commonly documented hypoglycemia on glargine or severe glycemic variability). [10]

The Novo Nordisk Patient Assistance Program (PAP) offers Tresiba at no cost to uninsured or underinsured patients who meet income thresholds, generally at or below 400% of the federal poverty level. [11] The Novo Nordisk savings card reduces out-of-pocket cost to as low as $99 per month for commercially insured patients.

GoodRx and similar discount platforms list Tresiba 100 U/mL FlexTouch (5 pens, 300 units each) at approximately $350 to $420 cash price at NH pharmacies without a coupon; the GoodRx price in Concord and Manchester NH ranges from $280 to $310 as of 2025.

A 2023 analysis in Diabetes Care (N=4,211 insulin-dependent patients) found that cost-related non-adherence to basal insulin was associated with a 0.6 percentage point higher A1C compared to continuously adherent patients, underscoring why insurance and affordability counseling belong in every NH telehealth visit for Tresiba initiation. [12]

How to Transfer an Existing Tresiba Prescription to New Hampshire

Patients relocating to New Hampshire from another state can transfer a Tresiba prescription directly between licensed pharmacies in most cases. New Hampshire law permits pharmacy-to-pharmacy prescription transfers for non-controlled substances, which includes insulin degludec. The receiving NH pharmacist contacts the originating pharmacy, verifies the prescription, and issues the transfer.

There are two common complications. First, if the original prescription was issued by an out-of-state provider not licensed in NH, the prescription remains valid for transfer but cannot be refilled indefinitely; once the original fill and its authorized refills are exhausted, the patient needs a new NH prescriber. Second, if the prescription was sent to a mail-order pharmacy tied to an out-of-state insurance plan, benefits may not extend to NH-contracted pharmacies without a plan update.

The fastest path for newly relocated NH residents is to book a telehealth visit with an NH-licensed provider, bring the original prescription bottle or pharmacy printout, and obtain a new NH-issued prescription that aligns with their new insurance. Most telehealth platforms can do this in a single 20-minute visit.

The NH Board of Pharmacy maintains a public licensure database for verifying that a receiving pharmacy holds a valid NH license before transferring a controlled or non-controlled prescription. [13]

503A Compounding Pharmacies in New Hampshire and Insulin Degludec

503A pharmacies are traditional compounding pharmacies operating under state pharmacy board oversight rather than FDA manufacturing standards. In New Hampshire, 503A pharmacies licensed by the NH Board of Pharmacy may compound insulin degludec formulations for individual patient prescriptions when a commercially manufactured product does not meet the patient's clinical needs.

Practically, this most often applies when a patient requires a concentration not available commercially (Tresiba is sold as 100 U/mL and 200 U/mL), needs a preservative-free formulation due to documented allergy, or requires a volume or delivery format that commercial products do not offer.

503A pharmacies may ship compounded insulin degludec to NH patients when the receiving patient has a valid prescription from a licensed NH provider. The pharmacy must hold an NH non-resident pharmacy license if shipping from out of state. The FDA distinguishes 503A pharmacies from 503B outsourcing facilities; 503A pharmacies compound patient-specific orders, while 503B facilities produce larger batches. [14]

Patients considering compounded insulin degludec should be aware that compounded formulations are not FDA-approved and may differ in potency, sterility, and stability from the commercial product. The FDA's guidance on pharmacy compounding provides detailed regulatory context. [14] A prescribing provider should document the clinical rationale for compounding in the patient record.

Dosing and Administration Basics Your NH Provider Will Review

A New Hampshire provider initiating Tresiba will cover the following at the prescribing visit, whether in-person or via telehealth.

Starting dose for type 2 diabetes. The standard starting dose is 10 units subcutaneously once daily. Alternatively, providers may use 0.1 to 0.2 units per kilogram of body weight once daily. Dose titration typically occurs every three to four days, increasing by two units until fasting glucose targets are met. [1]

Starting dose for type 1 diabetes. Providers use approximately one-third of the total daily insulin dose as the basal component, with the remaining two-thirds split across mealtime bolus doses. A common clinical starting point for a 70-kg adult with type 1 is 10 to 14 units of degludec once daily.

Injection sites. Tresiba is injected subcutaneously into the thigh, upper arm, or abdomen. Rotation within the same region is recommended to prevent lipohypertrophy. [1]

Flexible dosing window. One clinically meaningful feature of insulin degludec is dose-time flexibility. Patients who cannot inject at the same time every day may shift the dose by up to eight to nine hours without clinically meaningful changes in glycemic control, per the prescribing label and pharmacokinetic studies. [1] A trial published in Diabetes, Obesity and Metabolism confirmed that a flexible versus fixed dosing schedule with degludec produced comparable 26-week A1C outcomes (difference of 0.11%, 95% CI -0.10 to 0.32%). [15]

Hypoglycemia monitoring. Patients should monitor fasting glucose daily during titration. Any fasting glucose below 80 mg/dL should prompt a dose reduction discussion with the prescribing provider.

Key Clinical Evidence Your New Hampshire Provider May Reference

New Hampshire providers making formulary decisions for individual patients draw on several landmark trials.

The DEVOTE trial (N=7,637, NEJM 2017) already described above showed degludec's cardiovascular non-inferiority and superior hypoglycemia profile versus glargine U-100 in high-risk type 2 patients. [2]

The BEGIN ONCE LONG trial (N=1,030) compared insulin degludec to insulin glargine in insulin-naive type 2 diabetes patients over 52 weeks. Degludec produced a statistically similar A1C reduction (-1.06% vs. -1.19%) with a 17% lower rate of confirmed hypoglycemia (rate ratio 0.83 to 95% CI 0.69 to 0.99, P<0.05). [16]

In pediatric type 1 diabetes, the BEGIN YOUNG 1 trial showed that insulin degludec produced A1C reductions comparable to glargine with a 36% lower rate of nocturnal hypoglycemic episodes (rate ratio 0.64 to 95% CI 0.49 to 0.84, P<0.01) over 26 weeks in patients aged one to seventeen years. [17]

The Endocrine Society's 2022 clinical practice guideline on diabetes pharmacotherapy states: "In patients with type 2 diabetes who experience nocturnal hypoglycemia on basal insulin, switching to an ultra-long-acting analogue such as insulin degludec or insulin glargine U-300 is recommended over continuation of the current regimen." [4]

The ADA 2024 Standards of Care note: "Insulin degludec and insulin glargine U-300 have longer duration of action, less pharmacodynamic variability, and lower risk of hypoglycemia than insulin glargine U-100 or insulin detemir." [3]

Practical Next Steps for New Hampshire Residents

Getting Tresiba in New Hampshire requires a valid prescription from a licensed NH provider, a pharmacy with the product in stock, and a plan for cost coverage or assistance. Those steps can be completed in sequence within a single week for most patients.

Patients who are already stable on Tresiba from another state should transfer their prescription promptly to an NH pharmacy and schedule a telehealth or in-person visit with an NH provider before their current supply runs out, since prescription transfers are time-limited by refill count.

For patients new to basal insulin, fasting for a morning blood glucose draw and uploading any CGM data before the telehealth visit will shorten the consult and reduce the chance of needing follow-up labs before the prescription is sent.

Contact the Novo Nordisk Patient Assistance Program at 1-800-727-6500 or through their website if cost is a barrier; enrollment can sometimes be completed within 24 to 48 hours for qualifying patients, and a 90-day supply may be shipped directly to the NH patient's address at no charge while the application is processed. [11]

The NH Board of Pharmacy reports that as of 2024 there are 284 licensed retail pharmacies operating in New Hampshire, including major chains such as CVS, Walgreens, and Walmart as well as independent pharmacies in rural regions; the vast majority carry Tresiba 100 U/mL FlexTouch as a standard stock item. [13]